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DNA viruses such as herpesviruses are known to encode homologs of cellular antiapoptotic viral Bcl-2 proteins (vBcl-
2s), which protect the virus from apoptosis in its host cell during virus synthesis. Epstein-Barr virus (EBV), a human
tumor virus and a prominent member of c-herpesviruses, infects primary resting B lymphocytes to establish a latent
infection and yield proliferating, growth-transformed B cells in vitro. In these cells, 11 viral genes that contribute to
cellular transformation are consistently expressed. EBV also encodes two vBcl-2 genes whose roles are unclear. Here we
show that the genetic inactivation of both vBcl-2 genes disabled EBV’s ability to transform primary resting B
lymphocytes. Primary B cells infected with a vBcl-2-negative virus did not enter the cell cycle and died of immediate
apoptosis. Apoptosis was abrogated in infected cells in which vBcl-2 genes were maximally expressed within the first
24 h postinfection. During latent infection, however, the expression of vBcl-2 genes became undetectable. Thus, both
vBcl-2 homologs are essential for initial cellular transformation but become dispensable once a latent infection is
established. Because long-lived, latently infected memory B cells and EBV-associated B-cell lymphomas are derived
from EBV-infected proapoptotic germinal center B cells, we conclude that vBcl-2 genes are essential for the initial
evasion of apoptosis in cells in vivo in which the virus establishes a latent infection or causes cellular transformation or
both.
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Introduction
Apoptosis is a mechanism used by the infected cell as part
of its antiviral response; cells can commit suicide as a direct
response to viral infection prior to viral maturation.
Therefore, regulating apoptosis during infection is a high
priority for many viruses that frequently encode Bcl-2-like
mechanisms to do so [1]. Cellular Bcl-2 was originally
discovered as an oncogenic protein in follicular lymphomas
and up to now many Bcl-2 family members have been
identiﬁed that share distinct domains of high sequence
homology. Bcl-2 family members include apoptosis-inhib-
itory proteins, such as Bcl-2 and Bcl-XL, or those that
mediate proapoptotic functions exempliﬁed by Bax. All viral
Bcl-2 (vBcl-2) homologs identiﬁed so far block apoptosis.
The major role of vBcl-2 proteins is therefore to prevent
premature death of the host cell during virus production,
which would otherwise reduce the amount of progeny virus
[2,3]. Adenovirus E1B 19K, for example, is a minimal version
of the cellular Bcl-2 prototype, which prevents premature
cell death during productive infection. Bcl-2 and E1B 19K
can functionally substitute for each other in the suppression
of apoptosis during virion synthesis and oncogenic trans-
formation [1,3]. While members of the c-herpesvirus family
carry one vBcl-2 gene in general, Epstein-Barr virus (EBV)
encodes two Bcl-2 homologs, BALF1 and BHRF1. The BHRF1
protein clearly resembles Bcl-2 in its antiapoptotic function
during in vitro assays [4], while the role of BALF1 is
controversial [5,6]; however, no function has been assigned
to either BALF1 or BHRF1 in the context of viral infection
[1,7]. Interestingly, vBcl-2 homologs have not been recog-
nized to contribute to viral latent infection directly [2,8,9],
probably because viral latency can only be studied with very
few viruses. In addition, functions involved in viral ‘‘ﬁtness’’
often overlap with speciﬁc functions, which contribute
directly to initiation and maintenance of viral latency in
vivo [10–12].
EBV provides a unique in vitro model, which permits the
dissection of viral contributions to latent infection. EBV can
infect all cells of the B-cell lineage, but its main targets in
vivo are naı ¨ve B cells and B cells that undergo afﬁnity
maturation during a germinal center reaction to establish
long-term latent infections in memory B cells [13,14]. In vivo
and in vitro EBV’s latent state is characterized by the
absence of virus synthesis and maintenance of the viral
genome as plasmids in the infected cell. In vitro, EBV infects
resting human B lymphocytes and transforms them into
lymphoblastoid cell lines (LCLs), a process that is termed
growth transformation and a hallmark of this virus. In LCLs,
11 so-called latent genes are consistently expressed. These
Received July 4, 2005; Accepted September 27, 2005; Published November 15,
2005
DOI: 10.1371/journal.pbio.0030404
Copyright:  2005 Altmann and Hammerschmidt. This is an open-access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Abbreviations: BrdU, 5-bromo-29-deoxyuridine; EBV, Epstein-Barr virus; FACS,
fluorescence-activated cell sorting; GFP, green fluorescence protein; GRU, green
Raji unit; kbp, kilobasepairs; LCL, lymphoblastoid cell line; MOI, multiplicity of
infection; p.i., postinfection; PI, propidium iodine; vBcl-2, viral Bcl-2
Academic Editor: Bill Sugden, University of Wisconsin at Madison, United States of
America
*To whom correspondence should be addressed. E-mail: hammerschmidt@gsf.de
PLoS Biology | www.plosbiology.org December 2005 | Volume 3 | Issue 12 | e404 2148
Open access, freely available online PLoS BIOLOGYare the EBV nuclear antigens EBNA1, EBNA2, EBNA-LP,
EBNA3A, -B, -C, and the latent membrane proteins LMP1,
LMP2A, and -B, and two noncoding RNAs [15]. Genetic and
biochemical experiments demonstrate that several of these
viral proteins directly contribute to growth transformation
and latency of infected cells in vitro and in vivo, although
only a subset of these 11 genes are expressed in the human
host [16]. Typically, latent genes of EBV mimic cellular
functions. For example, the viral proteins LMP1 and LMP2A
target physiological signaling pathways, which are engaged
by the B-cell and CD40 receptors upon contact with antigen
and T helper cells, respectively. LMP1 and LMP2A are also
expressed in EBV-positive B-cell lymphomas such as
Hodgkin’s disease and posttransplant lymphomas [13], which
are two of several malignancies with which EBV has been
associated [16,17]. LMP1 indirectly inhibits apoptosis by
upregulating several cellular antiapoptotic genes [18],
presumably through the induction of the NF-jB pathway
[19–21]. LMP1 promotes cell proliferation [18,22] and scores
as an oncogene in transgenic animals [23]. In LCLs, but not
in EBV-associated tumors, LMP1 and LMP2A are transcrip-
tionally upregulated by EBNA2, which is the ﬁrst latent viral
gene expressed after infection of B cells in vitro. EBNA2 is
the key viral factor, which is essential for in vitro growth
transformation of resting primary B cells [24,25], along with
LMP1 [26], EBNA1 [15], EBNA3A, and -C [27]. This minimal
set of ﬁve latent EBV genes has been regarded as sufﬁcient
to yield growth-transformed LCLs in vitro [15], although the
requirements for EBNA3A, EBNA1, and LMP1 appear to be
less stringent [28–30]. None of the known latent gene
products of EBV directly regulate apoptosis, and little is
known about viral genes expressed very early in primary B
cells upon viral infection.
We analyzed the two vBcl-2 genes of EBV—BHRF1 and
BALF1—and demonstrate that their gene products in
addition to the known latent EBV genes are essential for
the process of B-cell transformation. The vBcl-2 homologs
are maximally expressed initially after infection but are
neither expressed nor required once a latent infection is
established. The very early expression of vBcl-2 genes
prevents EBV-infected B cells from undergoing sponta-
neous programmed cell death and is mandatory to
establish a latent infection and cause cellular transforma-
tion. We conclude that EBV employs a biphasic control—
characterized by viral genes expressed transiently and
those that are expressed stably—to initiate and maintain
a latent infection.
Results
vBcl-2 Genes Are Essential for Growth Transformation of
Resting B Cells but Dispensable for Proliferating B Blasts
In order to gain insight into the function of BALF1 and
BHRF1, we constructed several viral mutants, which carry
singly or dually inactivated alleles of BALF1 and BHRF1
(Figure 1A and 1B). Mutant virus stocks were generated as
described [31]. Surprisingly, virus production was not im-
paired even in the case of the dually inactivated vBcl-2
mutants, and transcomplementation of either BALF1 or
BHRF1 in virus-producing cells did not yield higher titers
(data not shown). Virus stocks were quantiﬁed by infecting
Raji cells, an established B-cell line [29]. Because our
recombinant EBVs encode green ﬂuorescence protein (GFP),
we could measure the concentration of GFP-transducing
virions as ‘‘green Raji units’’ (GRUs), which were in the range
of 10
4–10
5/ml GRUs similar to wild-type 2089 EBV stocks [32].
Primary B cells were infected with serial virus dilutions to
determine the number of GRUs required statistically to give
rise to clonal LCLs [33]. Two GRUs were sufﬁcient in the case
of 2089 wild-type EBV, and the single BALF1
– or BHRF1
–
mutants were equally capable of yielding clonal LCLs but at a
slightly higher virus dose (Figure 1B–1D). Two independent
viral mutants with inactivated vBcl-2 genes failed to generate
LCLs, even at a dose of 10
4 GRUs per well (Figure 1C and 1D).
Reconstruction of the BALF1 allele in the revertant BALF1
þ/
BHRF1
  virus reconstituted EBV’s capacity to growth trans-
form human B lymphocytes (Figure 1C and 1D).
We determined whether infection of preactivated human B
cells might overcome the failure of the vBcl-2
  mutants to
establish growth transformed LCLs from resting primary B
cells. B blasts, which can be generated from resting primary B
cells by cocultivation on CD40 ligand-expressing feeder cells
in conjunction with IL-4, proliferate in vitro and express
cellular antiapoptotic Bcl-2 family members, which are
upregulated through the CD40 and JAK/Stat-induced signal-
ing pathways [34,35]. The continued proliferation of B blasts
is totally dependent on both activating stimuli. Upon removal
of either CD40L or IL-4 signals, the B blasts cease to
proliferate immediately and undergo apoptosis within 10 d
(data not shown). Limiting dilution assays with activated B
blasts as target cells and serially diluted BALF1
 /BHRF1
  2636
virus (Figure 1B) resulted in clonal LCLs, which proliferated
in the absence of either CD40L or IL-4 signals, indicating that
preactivated B cells compensate for the functional defect of a
vBcl-2
  virus (Figure 1E). Once established, these LCLs
infected with vBcl2
  EBV proliferated normally and did not
show an apparently different phenotype when compared with
wild-type EBV-infected LCLs (data not shown).
vBcl-2 Genes Are Maximally Expressed Very Early After EBV
Infection of Primary B Cells
Eleven EBV genes have previously been identiﬁed as being
constitutively expressed in established LCLs. Neither BALF1
nor BHRF1 is among this group, however [15,36]. Latent EBV
genes such as EBNA2 and LMP1 encode key regulators of
cellular proliferation, which are required to initiate and
maintain proliferation of lymphoblastoid cells in vitro [22,24–
26,37]. Therefore, we set out to analyze the expression kinetics
of BALF1 and BHRF1 in infected primary B cells. As shown in
Figure 2, upon infection with the B95.8 prototype EBV strain,
BHRF1 and BALF1 transcripts were readily detected within 24
h postinfection (p.i.) but not in cells infected at 4 8Co ri n
uninfected cells (Figure 2A and 2E). Whereas EBNA2 is
constitutively expressed in established latently infected LCLs
(data not shown [15]), the expression of both BALF1 and
BHRF1 rapidly decreased, and their transcripts were weakly
or not detected by RT-PCR 3 wk p.i. (Figure 2A and 2E).
EBNA2 transcripts could be detected 1 d p.i. in wild-type 2089
EBV or 2636 BALF1
 /BHRF1
 mutant infected primary B cells
(Figure 2B). Similarly, vBcl-2 transcripts are readily detectable
in cells infected with an EBNA2
– 2491 mutant EBV (Figure
2C), indicating that EBNA2 and vBcl-2 genes are independ-
ently expressed very early after infection.
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Viral Bcl-2 Homologs in Latent InfectionAs expected, BALF1 and BHRF1 were not expressed in
other latently EBV-infected cells (Figure 2D) but readily
detectable in cells that spontaneously support the lytic phase
of EBV’s life cycle (B95.8 cells in Figure 2A and 2D) and
maximally expressed in cells in which the lytic phase was
induced (Figure 2D). Because both vBcl-2 genes were induced
during EBV’s lytic phase, and several reports indicate that
lytic expression of BHRF1 is strictly dependent on the
immediate-early transcriptional activator BZFL1 ([15,38]
and references therein), we wanted to learn whether initial
expression of BALF1 or BHRF1 in newly infected primary B
cells is also regulated by BZLF1. BZLF1 encodes a molecular
switch protein, which is instrumental in inducing the lytic
phase in latently EBV-infected cells ([15] and references
therein). The EBV mutant 2809, which is BZLF1
  [39], was
used to infect primary B cells, and the expression of BALF1
and BHRF1 was assessed by RT-PCR. Again, vBcl-2 transcripts
were readily detectable in cells infected with the BZFL1
 2809
EBV mutant, indicating that BZLF1 does not regulate BALF1
and BHRF1 expression (Figure 2C). As expected, EBNA2
expression was also BZLF1 independent (Figure 2B).
Cell Cycle Activation Is Abrogated in vBcl-2
– EBV-Infected
Cells
We questioned whether vBcl-2 gene products might be
critical for cell cycle entry similar to EBNA2 [15,40]. Stocks of
the BALF1
 /BHRF1
  2636 virus were used to infect primary B
cells at a multiplicity of infection (MOI) of 0.5 GRU with the
EBNA2
  mutant 2491 or wild-type EBV 2089 serving as
controls. For direct comparison, a fraction of the cells was left
uninfected. The cell cycle status of the cells was analyzed by 5-
bromo-29-deoxyuridine (BrdU)-incorporation and ﬂuores-
cence-activated cell-sorting (FACS) analysis, which revealed
cycling cells in wild-type EBV-infected cells as early as day 3
p.i. (Figure 3). Uninfected cells did not enter the cell cycle nor
did the cells infected with the EBNA2
 or the BALF1
 /BHRF1
 
2636 mutants. These latter infected cells all showed a rapid
increase in the fraction of cells with a subG1 DNA content
indicating that the inactivation of both vBcl-2 genes pre-
vented cell cycle entry similar to EBNA2
  EBV, which lacks
the key regulator of EBV’s latent genes (Figure 3).
B-Cell Apoptosis Is Delayed in vBcl-2
þ EBV-Infected
Primary B Cells
Given that EBNA2 is a pivotal mediator of EBV’s known
latent genes, it is important to know if EBV’s vBcl-2 genes,
which are required to establish latency (see Figure 1), depend
on any of EBNA29s functions. We tested whether primary B
cells infected with the EBNA2
– mutant, which is capable of
expressing both vBcl-2 genes (see Figure 2C), showed a
phenotype different from cells infected with a mutant null
for vBcl-2s. Because both viral mutants are deﬁcient in
inducing cellular proliferation (see Figure 3), we could
concentrate on effects related to apoptotic markers inde-
pendent of global cellular activation (Figure 4). Toward this
end, we infected primary B cells with the EBNA2
  2491 or the
BALF1
 /BHRF1
  2636 viruses (or wild-type 2089 EBV as a
positive control) and determined the occurrence of GFP
þ
EBV-infected cells by FACS (Figure 4C). To monitor the
numbers of GFP
þ cells over a period of 8 d, calibration beads
were used as an internal reference (Figure 4A). By three-
parameter FACS analysis, GFP
þ B cells were also analyzed for
binding of Annexin-V and propidium iodine (PI) uptake as
indicators of early apoptosis and loss of membrane integrity,
respectively (Figure 4D). In parallel, uninfected cells with
typical lymphocytic characteristics by forward and sideward
scatter criteria (Figure 4B) were compared for their Annexin-
V and PI staining. As shown in Figure 4D and 4E, uninfected
primary B cells as well as those infected with BALF1
 /BHRF1
 
2636 mutant rapidly lost their viability. As early as day 3 p.i.,
about 70% of the BALF1
 /BHRF1
  virus-infected cells were
Annexin-V
þ/PI
þ comparable to uninfected cells. By day 5, few
lymphocytes had survived and none were found on day 8
(Figure 4E). In stark contrast, all primary B cells infected with
the EBNA2
 mutant 2491, which expressed BALF1 and BHRF1
transcripts immediately after infection (see Figure 2C), were
alive on day 3 p.i., about 15% survived until day 5, and a few
percent of the cells were GFP
þ/Annexin-V
 /PI
 8 d p.i. (Figure
4D and 4E). Thus, EBV’s Bcl-2 homologs support initial B-cell
s u r v i v a la n dr e s c u eE B V - i n f e c t e dBc e l l s ,w h i c hw o u l d
otherwise succumb rapidly to spontaneous apoptosis.
Discussion
vBcl-2 Genes Are Essential for Growth Transformation of
Primary B Lymphocytes
Some viruses encode proteins that interfere with the host’s
apoptotic machinery to ensure short-term cell survival and to
yield progeny before the cell lyses and dies [3,41,42].
Similarly, c-herpesviruses encode vBcl-2 genes, whose gene
products are antiapoptotic Bcl-2 family members and act
during productive infection or contribute to viral virulence
[10,12]. Only EBV is known to encode two Bcl-2 homologs,
BALF1 and BHRF1. BHRF1 was shown to be dispensable for
B-cell growth transformation [43,44], but its product does
have antiapoptotic functions [4,45]. The function of the
BALF1 gene product is controversial [5,6]. Our experiments
Figure 1. Construction and Genealogy of EBV Mutants and Their Efficiency of B-Cell Growth Transformation
(A) Construction of the loss of function mutation in BALF1 and BHRF1. (B) Wild-type (WT) 2089 EBV is based on the genome of the EBV strain B95.8. The
BALF1 and BHRF1 genes were inactivated through insertional mutagenesis with antibiotic resistance genes. Two vBcl-2 mutants 2636 and 2765 were
constructed independently on the basis of the singly inactivated viruses, and the BALF1
 /BHRF1
  mutant 2636 was reverted to BALF1
þ/BHRF1
 . (C) The
numbers indicate the number of GRUs of the virus stocks, which were required to yield one clonal LCL for each virus noted in (B). (D) Efficiency of B-cell
growth transformation. The different singly and dually vBcl-2
  EBV virus mutants were compared with wild-type 2089 EBV for their efficiencies to
growth transform primary B cells in limiting dilution assays. Forty-eight wells with 10
5 target B cells per well were infected with each virus dilution, and
wells with proliferating cells were recorded 6 wk p.i. The data are graphed to identify the number of GRUs of the different virus isolates required to yield
one LCL. The horizontal line at 30 wells positive for 48 wells plated identifies for a Poisson distribution the required number of GRUs shown on the x-
axis. Infection of primary B cells with the vBcl-2
  mutants 2636 and 2765 did not yield stable LCLs even with up to 10
4 GRUs per 10
5 cells per well. (E)
Comparison of the efficiency of wild-type 2089 EBV and the BALF1
 /BHRF1
  mutant 2636 to yield stable, clonal LCLs in limiting dilution assays with
primary B cells or activated B blasts as target cells. Activated B blasts readily gave rise to LCL clones with the BALF1
 /BHRF1
 mutant 2636 in contrast to
the situation in (D), although about 200 GRUs were statistically required to establish clonal lines, which all could be further expanded and characterized
(data not shown).
DOI: 10.1371/journal.pbio.0030404.g001
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Viral Bcl-2 Homologs in Latent Infectionindicate that (i) both BALF1 and BHRF1 belong to the same
genetic complementation group and are functionally redun-
dant (see Figure 1). Either BALF1 or BHRF1 is (ii) essential to
establish latently infected LCLs (see Figures 1 and 3) but (iii)
dispensable for their continued proliferation (see Figure 1E)
and (iv) generation of virus progeny (data not shown). In
newly infected primary B cells, (v) both vBcl-2 genes are
expressed immediately but transiently after infection (see
Figure 2), in contrast to the group of 11 latent EBV genes,
which are constitutively expressed [15,46]. Surprisingly,
BALF1 and BHRF1 proteins (vi) prevent spontaneous pro-
grammed cell death in newly infected resting primary B cells
(see Figure 4). This newly identiﬁed function of vBcl-2
ensures successful infection of primary B cells, gives rise to
latent infection, and supports growth transformation of
resting B cells in vitro.
This ﬁnding seems to be without precedent because vBcl-2
homologs have not been recognized to contribute to viral
latent infection directly [2,8,9], probably because herpesviral
latency can only be studied with a few viruses. Similar to EBV,
long-term latency of the murine c-herpesvirus MHV-68 is
narrowly conﬁned to cells expressing a B-cell phenotype
[47,48]. Infection of mice with MHV-68 provides a tractable
and authentic animal model to study herpesviral latency in the
context of its natural host. A viral mutant deﬁcient for the
MHV-68vBcl-2geneM11wasfoundcompromisedinreactivat-
ingfromlatency [12], whereasa morerecent paperidentiﬁeda
vBcl-2 associated deﬁcit in establishment of latency [10].
Although the molecular basis for these observations remains
unclear, both seem to be consistent with vBcl-2 protecting
latently infected B cells from apoptotic death. Similar to our
ﬁndings, no role for vBcl-2 of MHV-68 was apparent during
acute viral replication in vivo or viral virulence [10–12].
How Are vBcl-2 Genes Regulated in Newly Infected
Primary B Cells?
Experimental data clearly demonstrate that BALF1 and
BHRF1 are maximally expressed in primary B cells within 24
h p.i. (see Figure 2A). Because the expression of BALF1 and
BHRF1 is also prominent during EBV’s lytic phase (see Figure
2D), we wondered whether their expression might be
regulated by the viral immediate-early gene BZLF1. BZLF1
is a transcription factor and acts like a molecular switch to
induce the lytic phase in latently EBV-infected cells ([15] and
references therein). Unexpectedly, the expression of both
vBcl-2 genes was found to be independent of BZLF1 (see
Figure 2C). Thus, we do not know the mechanisms regulating
the expression of both BALF1 and BHRF1, but we would like
to speculate that both genes are directly and spontaneously
expressed from the transducing EBV genome. The herpesvi-
ral DNA delivered to the nucleus of the infected cell is
unmethylated, coated with polyamines [49], and not in a
Figure 2. Detection of EBNA2, BALF1, and BHRF1 Transcripts by RT-PCR
Analysis
(A). Primary B cells were infected with B95.8 EBV, and RNA was prepared
at various time points. The expression of BALF1, BHRF1, and HPRT (as
control) was analyzed by RT-PCR. (B). Primary B cells were infected with
wild-type 2089 EBV, the BZFL1
  mutant 2809, or the BALF1
 /BHRF1
 
mutant 2636 (MOI 0.1), and the expression of EBNA2 was determined by
RT-PCR. EBNA2 mRNA was detectable in comparable amounts in cells
infected with either virus stock on day 1 and on day 5 p.i. (C). Primary B
cells were infected with wild-type 2089 EBV, the BZFL1
  mutant 2809, or
the EBNA2
  mutant 2491. Similar to (A), vBcl-2 transcripts were
detectable in comparable amounts in cells infected with either virus
stock on day 1 and on day 5 p.i. but at a reduced level on day 5. (D).
BALF1 and BHRF1 transcript levels in latently infected and lytically
induced cell lines. Neither BALF1 nor BHRF1 are detectably expressed in
the latently infected, EBV-positive Akata cell line [62] or in 293HEK cells
stably transfected with wild-type 2089 EBV. Both mRNAs are easily
detectable in B95.8 cells, which spontaneously support productive
infection, or in lytically induced 293HEK cells carrying the maxi-EBV
2089). (E) Schematic overview of the PCR primers and their location used
to detect EBNA2-, BALF1-, or BHRF1-specific cDNAs. The PCR product
indicative of correctly spliced EBNA2 transcripts is 426 bp in length; the
BALF1 PCR product is 443 bp in length. BHRF1-specific PCR products are
expected to be 551 bp and 991 bp in length, representing the spliced
and unspliced transcripts, respectively.
DOI: 10.1371/journal.pbio.0030404.g002
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Viral Bcl-2 Homologs in Latent Infectionchromatin-like state [50], which should permit universal
access of the transcriptional machinery to many viral
promoter elements. Modiﬁcations of the EBV genomic DNA
over time will alter its accessibility, which might cause a rapid
decline in the expression of BALF1 and BHRF1 when the virus
eventually establishes a genuine latent infection (see Figure
2A).
vBcl-2 Homologs Are Likely to Be Involved in In Vivo
Latency and Oncogenesis of EBV-Associated Tumors
EBV-associated B-cell lymphomas originate from germinal
center B cells, which are inherently prone to apoptosis as they
undergo afﬁnity maturation and somatic hypermutation in
their B-cell receptor genes, events characteristic of this stage
Figure 3. Cell Cycle Analysis of Uninfected Primary B Cells (PBls) or PBls Infected with EBNA2
 Virus, BALF1
 /BHRF1
 Mutant 2636, or Wild-Type 2089 EBV
Primary B cells (10
5) per time point were infected with a viral dose such that about 50% of the cells were infected or left uninfected, and their cell cycle
profiles were determined by BrdU incorporation and FACS analysis. Only wild-type 2089 EBV induced cell cycle progression, whereas uninfected cells as
well as cells infected with the two mutants became apoptotic as indicated by their subG1 DNA content. (A) shows the compiled data of the primary
results, which are illustrated in (B). One representative experiment out of three is shown.
DOI: 10.1371/journal.pbio.0030404.g003
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Viral Bcl-2 Homologs in Latent Infectionof B-cell differentiation. It is unclear whether EBV infects
naı ¨ve B cells prior to their germinal center passage [51,52] or
germinal center B cells directly [53]. Our data indicate in
either case that BALF1 and BHRF1 are involved in the in vivo
survival of EBV-infected CD77
þgerminal center B cells. These
cells normally are highly sensitized to apoptotic signals, and
most will be eliminated via programmed cell death [54]. EBV
is expected to provide an important signal or signals to
prevent apoptosis common to germinal center B cells because
a fraction of EBV-infected and malignant tumor cells contain
only nonfunctional B-cell receptor genes and would have
been expected to undergo programmed cell death. EBV’s
vBcl-2 proteins likely constitute this survival signal, which
would be superseded by the eventual expression of LMP2A
[55,56] and/or other ‘‘classical’’ latent EBV genes. Thus, EBV’s
Bcl-2 homologs are likely to counteract the physiological
elimination of B cells, which might be a crucial viral
contribution to lymphomagenesis [13].
The physiological expansion of B cells during the germinal
center reaction increases the size of the pool of EBV-infected
cells, which go on to differentiate into long-lived memory B
cells, the reservoir for virus in vivo [51,52]. Because memory B
cells originate from functional survivors of the germinal
center passage, we favor the notion that during this passage
EBV’s antiapoptotic viral genes provide a survival advantage
to the infected cells favoring their developing into memory B
cells in which EBV is latent and can thereby establish a
lifetime relationship with its human host.
Materials and Methods
Construction of viral mutants. The BALF1
  and BHRF1
  single
deletion mutants were constructed on the basis of the wild-type B95.8
EBV strain cloned onto the F-factor plasmid p2089 [32]. The
inactivation of the vBcl-2 genes or the EBNA2 gene in the EBV
genome was carried out with two different genetic procedures as
described in a recent review [57]. To promote the integration of
linear DNA fragments in the DH10B Escherichia coli host, the
conditional recA/redc expression plasmid p2650 based on the pST76-
amp plasmid was employed. To generate the vBcl-2 targeting plasmids
for homologous recombination, subgenomic EBV DNA fragments of
about 10 kilobasepairs (kbp) in size, spanning either the BALF1 or the
BHRF1 locus, were subcloned to yield the plasmids p1352 and p528,
respectively. The BALF1 targeting plasmid p2564 was generated by
inserting the tetracycline resistance gene from pCP16 [58] into the
BALF1 open reading frame in p1352. The kanamycin phosphotrans-
ferase gene from pCP15 [58] was inserted into the BHRF1 coding
sequence of p528, giving rise to the targeting plasmid p2632.
Homologous recombinations were carried out with the p2089 maxi-
EBV genome to yield the EBV mutant genomes p2512 and p2637,
which carry singly inactivated BALF1 and BHRF1 genes, respectively
(see Figure 1A and 1B). The two BALF1
 /BHRF1
  and BHRF1
 /
BALF1
  mutants p2636 and p2765 were generated in a second round
of homologous recombination with the two targeting plasmids p2632
and p2564 (see Figure 1A and 1B). The BALF1
þ/BHRF1
  revertant
maxi-EBV p3227 with a reconstructed wild-type BALF1 gene was
generated with the aid of the pST76-amp-based shuttle plasmid [59]
carrying the wild-type BALF1 gene ﬂanked by homologous EBV
sequences. A cointegrate of the shuttle plasmid and the p2636 EBV
plasmid was formed with the ‘‘chromosomal-building’’ technique [60],
which led to the maxi-EBV construct p3227 after routine genetic
manipulations. The EBNA2
  EBV mutant 2491 was also constructed
with the chromosomal-building technique and the shuttle plasmid
p2419.1 to delete the entire coding sequences of the EBNA2 gene in
the context of the maxi-EBV genome 2089. The BZLF1
– EBV mutant
2809 was described [39]. The genetic compositions of the modiﬁed
EBV genomes were veriﬁed by restriction enzyme analysis, Southern
blot hybridization, and partial DNA sequencing. Details for the
generation of all EBV mutants are available upon request.
Preparation and quantiﬁcation of infectious viral vector stocks. On
the basis of 293HEK cells, stable cell lines were established after
individual transfection of the genomic maxi-EBV DNAs and
subsequent selection with hygromycin as described [29]. To obtain
virus stocks, the cell lines were transiently transfected with expression
plasmids encoding BZLF1 [61] and BALF4 [31] to induce EBV’s lytic
cycle. Four days p.i. supernatants were harvested and ﬁltered through
1.2-lm pore ﬁlters. The different EBV vector stocks were quantiﬁed
by infection of Raji cells as described [29,31]. Brieﬂy, 3 3 10
5 Raji
cells were incubated at 37 8C in 24-well cluster plates with different
dilutions of the virus stocks to be analyzed. The absolute number of
GFP
þ cells was determined by ultraviolet microscopy in a deﬁned
fraction of the total Raji cell population 4 d after infection. On the
basis of these data, GRUs per milliliter were calculated as a measure
of the concentration of infectious maxi-EBV particles in different
virus stocks. We used this titering method because other biologically
relevant readouts are not feasible with nontransforming EBV
mutants and very time-consuming with transformation-competent
wild-type EBV. Infection and evaluation of GFP
þ Raji cells under-
estimates the concentration of infectious EBV virions by a factor of at
least ten (data not shown).
Isolation, separation, and infection of primary B lymphocytes.
Human primary mononuclear cells were isolated from adenoids,
depleted of T cells by rosetting with sheep erythrocytes and puriﬁed
by Ficoll-Hypaque density-gradient centrifugation. The cell popula-
tion was further depleted of monocytes by plastic adherence for 1 h.
To quantify the efﬁciency of growth transformation with the
different virus stocks, 3 3 10
5 human primary B lymphocytes per
well were seeded in 96-well cluster plates on lethally irradiated Wi38
human ﬁbroblast feeder cells and infected with serially diluted virus
stocks with 2089 wild-type EBV and the different viral mutants in a
total volume of 100 ll as described [29]. Forty-eight wells were
infected with each single virus dilution. A 50-ll portion of medium
was exchanged every week for fresh medium, and the number of wells
with proliferating cells was determined 6 wk p.i. The infection
experiments with different viral mutants were independently
performed at least in triplicate. The experiments with activated B
blasts were carried out similarly. In order to generate proliferating
and activated B blasts, primary B lymphocytes were cultivated on an
irradiated CD40-ligand feeder cell layer [34] in the presence of 4 ng/
ml IL-4 (PAN Biotech, Aidenbach, Germany) and 1 lg/ml cyclo-
sporine A (Novartis, Basel, Switzerland) for several weeks prior to the
infection experiments. The proliferation of B blasts and their long-
term survival in vitro is strictly dependent on both CD40L and IL-4
generated signals. To quantify the number of GRUs needed to yield
clonal LCLs from B blasts, 3 3 10
5 blasts per well were seeded on an
Figure 4. Apoptosis of Primary B Cells
Primary B cells were infected with the EBNA2
 mutant 2491, the BALF1
 /BHRF1
 mutant 2636, or wild-type 2089 EBV, at an MOI of 0.1, or the cells were
left uninfected. Cells were analyzed by FACS at days 1, 3, 5, and 8 p.i. (A) Total cellular events were collected until 3 3 10
3 BD CaliBRITE beads as a
volume standard were counted. These beads, which are indicated by red circles in the FACS diagrams in (A) and (C), were used as an internal volume
reference corresponding to 3310
4 cells plated initially. (B) Uninfected cells that fulfilled the criteria of lymphocytes according to their forward (FSC) and
sideward (SSC) scatter characteristics were gated as indicated. One day after B-cell preparation, lymphocytes were present in the lymphocyte gate as
expected, but only a few lymphocytes were still present in this gate 8 d after cell preparation when the cells had been left uninfected. Similarly, EBV-
infected lymphocytes were selected according to the same scatter criteria (data not shown). (C) EBV-infected GFP
þ cells were gated as indicated. The
example shows an uninfected and a 2491 EBNA2
  EBV-infected B-cell sample with 3310
3 BD CaliBRITE beads added 1 d p.i. (D) Uninfected primary B
cells within the lymphocyte gate or EBV-infected GFP
þ lymphocytes were analyzed by FACS for Annexin-V binding and PI staining at different time
points p.i. The absolute numbers of Annexin-V
 /PI
 /GFP
þcells allowed the calculation of surviving cells at each time point p.i. Uninfected cells indicate
the rate and kinetics of spontaneous apoptosis of primary B cells ex vivo. Primary B cells infected with the BALF1
 /BHRF1
  mutant 2636 died as rapidly
as uninfected cells. Only B cells infected with the EBNA2
 mutant 2491, which is vBcl-2
þ, survived considerably longer. Primary B cells infected with wild-
type 2089 EBV as a positive control rapidly increased in the number of Annexin-V
 /PI
 /GFP
þ cells. (E) Summary of the primary data shown in (D).
Annexin-V
 /PI
 cells (uninfected control to determine spontaneous programmed cell death), or Annexin-V
 /PI
 /GFP
þ(infected) cells were set to 100% at
day 1, and the percentile of Annexin-V
 /PI
  cells at each time point was calculated. One representative experiment out of three is shown.
DOI: 10.1371/journal.pbio.0030404.g004
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serially diluted virus stocks as described above. Fifty percent of the
volume of the cell culture media was exchanged on a weekly basis,
and the cells were cultivated for 6 wk, during which the CD40-feeder
cell layer had completely disintegrated.
RT-PCR analysis. RNA was extracted from primary B cells with the
RNeasy Midi Kit (Qiagen, Valencia, California, United States); 5 lgo f
RNA was reverse transcribed with the Superscript III First Strand
Synthesis Kit (Invitrogen, Carlsbad, California, United States)
according to the manufacturer’s protocol in a total volume of 20 ll.
To monitor cellular DNA contamination of the RNA preparation,
PCR reactions were performed with primers for the abundant
cellular transcripts HPRT and ß-actin. PCR reactions for ß-actin were
an initial template denaturation of 4 min at 94 8C, with ampliﬁcation
for 25 cycles (1 min at 94 8C, 1 min at 61 8C, 1 min at 72 8C), followed
by a ﬁnal elongation for 10 min at 72 8C. PCR reactions for HPRT
were 4 min at 94 8C, with ampliﬁcation for 25 cycles (1 min at 94 8C, 1
min at 54 8C, 1 min at 72 8C), followed by a ﬁnal elongation for 10 min
at 72 8C. Two out of 20 ll of the cDNA reaction were used as
template. Unspliced PCR ampliﬁcation products indicative of cellular
DNA contamination were not detected (see Figure 2). PCR reactions
for cDNA detection of three EBV genes were as follows: EBNA2 (an
initial template denaturation of 4 min at 94 8C; 35 cycles of 1 min at
94 8C, 1 min at 61 8C, 1 min at 72 8C; followed by a ﬁnal elongation for
10 min at 72 8C); BHRF1 (an initial template denaturation of 4 min at
94 8C; 35 cycles of 1 min at 94 8C, 1 min at 54 8C, 1.5 min at 72 8C;
followed by a ﬁnal elongation for10 min at 72 8C); and BALF1 (an
initial template denaturation of 4 min at 94 8C; 35 cycles of 1 min at
94 8C, 1 min at 61 8C, 1 min at 72 8C; followed by a ﬁnal elongation for
10 min at 72 8C). Oligonucleotide primer sequences for the EBV
genes EBNA2, BALF1, and BHRF1 are provided in Figure 2E together
with their nucleotide coordinates of the EBV strain B95.8. The
primer sequences for HPRT cDNA detection were 59-GAGCTATTG
TAATGACCAGTC-39 and 59-CCAAACTCAACTTGAACTCTC-39;ß -
actin cDNA was ampliﬁed with the primers 59-CACCCTGTGCTGCT
CACCGAGGCC-39 and 59-ACCGCTCGTTGCCAATAGTGATGA-39.
Cell cycle analysis and analysis of apoptosis. Primary B cells (4 3
10
5) were infected with 4 3 10
4 GRUs of the different virus stocks in
20 ml of culture medium in order to obtain an MOI of 0.1. The cells
were kept on plastic, and at days 1, 3, 5, and 8 one-fourth of the
culture (5 ml) was harvested and further analyzed for cell cycle status
and apoptosis. Infection experiments were carried out with 2089
EBV, the EBNA2
  deletion mutant 2491, and the different mutant
virus stocks (see Figure 1); for a negative control the cells were left
uninfected. To determine the fraction of apoptotic cells, Annexin-V
staining was performed with the Annexin-V-APC kit (BioVision,
Mountain View, California, United States), according to the manu-
facturer’s protocol. For each time point, 5 ml of each sample was
harvested, spun, and the cells were stained with 5 ll of APC-coupled
Annexin-V and 5 ll of PI at a ﬁnal concentration of 10 lg/ml. As an
internal FACS calibration standard, 1 3 10
4 BD CaliBRITE Beads
(Becton-Dickinson, Palo Alto, California, United States) were added
to yield a ﬁnal concentration of 2310
4 beads/ml. The beads are very
small, resulting in a high intensity in the sideward scatter channel.
Since the beads also display a very bright APC ﬂuorescence, their
characteristics do not interfere with the cells to be analyzed but allow
their unbiased detection and quantiﬁcation. FACS analysis was
carried out in a FACS-Calibur machine (Becton-Dickinson). The 3
3 10
3 BD CaliBRITE Beads were set as a volume standard
corresponding to 3 3 10
4 cells plated initially to determine the
absolute number of cells at any given time point without interference
from the dynamics of the cell culture. To exclude cellular debris, only
cells within the lymphocyte gate were analyzed (see Figure 4B).
Cells infected with the different recombinant virus stocks express
GFP as early as day 1 p.i. The GFP gate was set such that only cells
with a GFP signal brighter than primary B cells infected with the
GFP
  prototypic B95.8 EBV strain scored positive as infected GFP
þ
cells (see Figure 4C). EBV-infected GFP
þ cells in the lymphocyte gate
were analyzed for their Annexin-V and PI staining. In uninfected
samples, only cells that fulﬁlled the criteria of lymphocytic cells by
forward and sideward scatter criteria were analyzed for both
Annexin-V and PI staining. The number of Annexin-V
 /PI
  cells in
the infected samples and the uninfected control were set to 100% at
day 1 p.i.
To analyze the cell cycle status of the infected primary B cells in
comparison to the uninfected controls, the samples were incubated
with the thymidine analog BrdU for 2 h prior to FACS analysis at
each time point. The cell proliferation assays were immediately
performed with the BrdU Flow Kit (BD Biosciences Pharmingen, San
Diego, California, United States). The cells were stained with an APC-
coupled BrdU-speciﬁc antibody after ﬁxation and permeabilization,
and the cellular DNA was counterstained with the DNA intercalating
dye 7-AAD according to the manufacturer’s protocol. FACS analysis
was performed until 3 3 10
4 cells were analyzed. The recorded data
were gated for cells in the G1, S, G2/M phases of the cell cycle and for




UniProtKB/TrEMBL (http://www.expasy.org/uniprot/) accession num-
bers for the proteins are Bax (Q07812), Bcl-XL (Q07817), Bcl-2
(P10415), CD40 receptor (P25942), LMP1 (P03230), LMP2A (Q777H4),
and LMP2B (Q8AZK9); for the virus, E1B 19K (P03247); for the genes,
BALF1 (Q777A6) and BHRF1 (Q777H0); for EBV nuclear antigens,
EBNA1 (P03211), EBNA2 (Q69023), EBNA3A (Q8AZJ8), EBNA3B
(Q777E8), EBNA3C (Q777E7), and EBNA-LP (Q8AZK7).
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